Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases.

Ercolani G, Cucchetti A, Cescon M, Peri E, Brandi G, Del Gaudio M, Ravaioli M, Zanello M, Pinna AD.

Eur J Cancer. 2011 Oct;47(15):2291-8. doi: 10.1016/j.ejca.2011.05.014. Epub 2011 Jun 7. Review.

PMID:
21652204
2.

Role of adjuvant therapy after resection of colorectal cancer liver metastases.

Power DG, Kemeny NE.

J Clin Oncol. 2010 May 1;28(13):2300-9. doi: 10.1200/JCO.2009.26.9340. Epub 2010 Apr 5. Review.

PMID:
20368552
3.

Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases?

Reddy SK, Tsung A, Marsh JW, Geller DA.

J Surg Oncol. 2012 Jan;105(1):55-9. doi: 10.1002/jso.22044. Epub 2011 Aug 12.

PMID:
21842519
4.

Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.

Gazelle GS, McMahon PM, Beinfeld MT, Halpern EF, Weinstein MC.

Radiology. 2004 Dec;233(3):729-39.

PMID:
15564408
5.
6.

Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy.

Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, D'Angelica M.

Ann Surg Oncol. 2007 Mar;14(3):1151-60. Epub 2006 Dec 31.

PMID:
17195913
7.

Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer.

Durand-Zaleski I, Roche B, Buyse M, Carlson R, O'Connell MJ, Rougier P, Chang AE, Sondak VK, Kemeny MM, Allen-Mersh TG, Fagniez PL, Le Bourgeois JP, Piedbois P.

J Natl Cancer Inst. 1997 Jun 4;89(11):790-5.

PMID:
9182977
8.

Colorectal cancer metastases: surgical indications and multimodal approach.

Ciferri E, Bondanza GS, Municinò O, Castagnola M, Gazzaniga GM.

Hepatogastroenterology. 2003 Nov-Dec;50(54):1836-46.

PMID:
14696416
9.

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.

Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Valentine WJ, Eiermann W.

J Med Econ. 2013;16(1):30-40. doi: 10.3111/13696998.2012.722572. Epub 2012 Sep 11.

PMID:
22966753
10.

A critical appraisal of the role of neoadjuvant chemotherapy for colorectal liver metastases: a case-controlled study.

Malik HZ, Farid S, Al-Mukthar A, Anthoney A, Toogood GJ, Lodge JP, Prasad KR.

Ann Surg Oncol. 2007 Dec;14(12):3519-26. Epub 2007 Oct 3.

PMID:
17912590
11.

Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.

Cucchetti A, Piscaglia F, Cescon M, Colecchia A, Ercolani G, Bolondi L, Pinna AD.

J Hepatol. 2013 Aug;59(2):300-7. doi: 10.1016/j.jhep.2013.04.009. Epub 2013 Apr 18.

PMID:
23603669
12.

Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group.

Van Den Brink M, Van Den Hout WB, Stiggelbout AM, Klein Kranenbarg E, Marijnen CA, Van De Velde CJ, Kievit J; Dutch Colorectal Cancer Group.

J Clin Oncol. 2004 Jan 15;22(2):244-53. Epub 2003 Dec 9.

PMID:
14665610
13.

Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases.

Durand-Zaleski I, Earlam S, Fordy C, Davies M, Allen-Mersh TG.

Cancer. 1998 Sep 1;83(5):882-8.

PMID:
9731890
14.

A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.

Tumeh JW, Shenoy PJ, Moore SG, Kauh J, Flowers C.

Am J Clin Oncol. 2009 Feb;32(1):49-55. doi: 10.1097/COC.0b013e31817c6a4d.

PMID:
19194125
15.

Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model.

Spolverato G, Vitale A, Ejaz A, Kim Y, Cosgrove D, Schlacter T, Geschwind JF, Pawlik TM.

Surgery. 2015 Aug;158(2):339-48. doi: 10.1016/j.surg.2015.03.033. Epub 2015 May 18.

PMID:
25999251
16.

Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.

Ishiguro H, Kondo M, Hoshi SL, Takada M, Nakamura S, Teramukai S, Yanagihara K, Toi M.

Clin Ther. 2010 Feb;32(2):311-26. doi: 10.1016/j.clinthera.2010.01.029.

PMID:
20206789
17.

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.

Am J Manag Care. 2006 Jul;12(7):374-86.

18.

Long-term characteristics of 5-year survivors after liver resection for colorectal metastases.

Tanaka K, Shimada H, Ueda M, Matsuo K, Endo I, Togo S.

Ann Surg Oncol. 2007 Apr;14(4):1336-46. Epub 2007 Jan 18.

PMID:
17235718
19.

Neo-adjuvant therapy improves resectability rates for colorectal liver metastases.

Shankar A, Leonard P, Renaut AJ, Lederman J, Lees WR, Gillams AR, Harrison E, Taylor I.

Ann R Coll Surg Engl. 2001 Mar;83(2):85-8.

20.

Colorectal hepatic metastases: resection, local ablation, and hepatic artery infusion pump are associated with prolonged survival.

Heslin MJ, Medina-Franco H, Parker M, Vickers SM, Aldrete J, Urist MM.

Arch Surg. 2001 Mar;136(3):318-23. Erratum in: Arch Surg 2001 Jul;136(7):809.

PMID:
11231853

Supplemental Content

Support Center